Comparing Factors Associated with Increased Stimulant Use in Relation to HIV Status Using a Machine Learning and Prediction Modeling Approach

Blair, Cheríe; Javanbakht, Marjan; Comulada, W. Scott; Bolan, Robert; Shoptaw, Steven; Gorbach, Pamina M.; Needleman, Jack

doi:10.1007/s11121-023-01561-x

Cited by 1 publication

(1 citation statement)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of social adversity and the efficacy of interventions in NHB PLWH and MSM living with HIV support Dr. Wakim-Takaki's biopsychosocial model, suggesting the need to address this dual diagnosis in a population-centered manner by addressing social, behavioral, and neurological mechanisms [15]. Machine learning is becoming a useful tool to identify biological, behavioral, and social determinants of SUD and HIV independently; however, to our knowledge, it has not been applied to identify predictors of comorbid HIV and SUD [193][194][195][196]. Data-driven models that predict determinants of comorbid HIV and SUDs will inform researchers and clinicians on developing more comprehensive diagnostic testing and population-and patient-centered care.…”

Section: Discussionmentioning

confidence: 99%

Neurological, Behavioral, and Pathophysiological Characterization of the Co-Occurrence of Substance Use and HIV: A Narrative Review

Vines,

Sotelo,

Giddens

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

Combined antiretroviral therapy (cART) has greatly reduced the severity of HIV-associated neurocognitive disorders in people living with HIV (PLWH); however, PLWH are more likely than the general population to use drugs and suffer from substance use disorders (SUDs) and to exhibit risky behaviors that promote HIV transmission and other infections. Dopamine-boosting psychostimulants such as cocaine and methamphetamine are some of the most widely used substances among PLWH. Chronic use of these substances disrupts brain function, structure, and cognition. PLWH with SUD have poor health outcomes driven by complex interactions between biological, neurocognitive, and social factors. Here we review the effects of comorbid HIV and psychostimulant use disorders by discussing the distinct and common effects of HIV and chronic cocaine and methamphetamine use on behavioral and neurological impairments using evidence from rodent models of HIV-associated neurocognitive impairments (Tat or gp120 protein expression) and clinical studies. We also provide a biopsychosocial perspective by discussing behavioral impairment in differentially impacted social groups and proposing interventions at both patient and population levels.

show abstract